# Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer

> **NCT07736937** · PHASE1,PHASE2 · RECRUITING · sponsor: **Gilead Sciences** · enrollment: 72 (estimated)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** TUB-040 + Carbo + BEV

## Key facts

- **NCT ID:** NCT07736937
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-30
- **Primary completion:** 2028-03
- **Final completion:** 2028-04
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2026-09-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07736937

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07736937, "Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07736937. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*